Merck (MRK) Short-Term Debt issuances (2009 - 2026)

Merck (MRK) reported Short-Term Debt issuances of $1.1 billion for Q1 2026, up 6973.33% quarter-over-quarter from $15.0 million in Q3 2025.

Merck (MRK) Short-Term Debt issuances (2009 - 2026) Analysis & Trends

Merck (MRK) has 15 years of Short-Term Debt issuances data on file, last reported at $1.1 billion in Q1 2026.

Short-Term Debt issuances for Q1 2026 came in at $1.1 billion, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (changed N/A YoY), and the FY2021 annual result was -$4.0 billion, down 256.38% from the prior year.
Short-Term Debt issuances grew to $1.1 billion in Q1 2026 per MRK's latest filing, from $15.0 million in the prior quarter.
Over five years, Short-Term Debt issuances peaked at $1.1 billion in Q1 2026 and troughed at $15.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ST Debt Issuance (Qtr)
1	Gsk	92,134,969.93 Bn	92,134,964.97 Bn	7.76 Bn	1.61 Bn
2	Eli Lilly	1,027.45 Bn	1,022.17 Bn	16.22 Bn	1.78 Bn
3	Johnson & Johnson	559.08 Bn	537.03 Bn	15.96 Bn	12.44 Bn
4	AbbVie	394.75 Bn	385.40 Bn	10.78 Bn	-499.00 Mn
5	Merck	295.12 Bn	289.47 Bn	12.09 Bn	1.06 Bn
6	Amgen	186.65 Bn	174.61 Bn	5.87 Bn	-
7	Gilead Sciences	159.22 Bn	151.50 Bn	5.52 Bn	-
8	Pfizer	146.00 Bn	133.23 Bn	-1.21 Bn	-127.00 Mn
9	Bristol Myers Squibb	113.22 Bn	102.77 Bn	8.07 Bn	321.00 Mn
10	Novartis Ag	108.02 Bn	107.33 Bn	-	747.00 Mn

Download Data